Naloxone Market

Naloxone is Fastest Growing Segment Fueling Growth of U.S. Naloxone Market

by

The global U.S. Naloxone Market is estimated to be valued at US$ 1,532.55 Mn in 2023 and is expected to exhibit a CAGR of 10% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:
Naloxone is an opioid antagonist used to block the effects of opioids in emergency situations like drug overdose or opioid poisoning. It works by reversing or blocking the effects of opioids, especially in overdose situations. Naloxone is administered through injection, nasal spray, or auto-injector devices to reverse life-threatening overdose effects.

Market key trends:
Rising opioid overdose deaths is driving the demand for easy-to-use naloxone products like nasal sprays and auto-injectors. According to the Centers for Disease Control and Prevention (CDC), more than 107,000 Americans died due to drug overdoses in 2021, with majority involving opioids. Increased adoption of naloxone prescription programs and community distribution through first responders and laypersons is expected to propel the U.S. naloxone market growth over the forecast period. Growing awareness about opioid overdose reversal and public health initiatives towards it would also contribute to industry expansion.

Segment Analysis
The U.S. naloxone market is segmented into types and distribution channels. By type, the market is divided into naloxone spray, intramuscular (IM) injection, and others. Among these, the naloxone spray segment accounts for the largest market share and is expected to remain dominant over the forecast period. Naloxone spray as an option for emergency treatment has gained wide acceptance due to its ease of use and administration. By distribution channel, the market is bifurcated into hospital pharmacies and retail pharmacies. The hospital pharmacies segment dominates the market due to increased access and higher productivity of opioid overdose treatment performed in hospitals.

Key Takeaways
Global U.S. Naloxone Market Size is expected to witness high growth, exhibiting a CAGR of 10% over the forecast period, due to increasing prevalence of opioid overdose.

North America dominates the global naloxone market, with the United States holding the largest market share. This is attributed to the growing rate of opioid overdose deaths and supportive government regulations and initiatives to curb the opioid crisis.

Key players operating in the U.S. naloxone market are Mylan N.V., Novartis AG, Indivior Plc., ADAPT Pharma, Inc., Amphastar Pharmaceuticals, Inc., INSYS Therapeutics, Inc., Mundipharma International Limited, Kaleo, Inc., Kern Pharma, S.L., Samarth Life Sciences Pvt. Ltd., Opiant Pharmaceuticals, Pfizer, Sandoz, and Amneal Pharmaceuticals. These key players are focused on developing generic as well as branded naloxone formulations to strengthen their positions in the market.

*Note:
1. Source: Coherent Market Insights, Public sources, Desk research
2. We have leveraged AI tools to mine information and compile it